PDF-HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include

WARNING DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning The effects of BOTOXand all botulinum toxin products may spread from the area of injection to produ. See full prescribing information for BIOTHRAX BIOTHRAX Anthrax Vaccine Adsorbed Suspension for Intramuscular or Subcutaneous Injection Initial US Approval 1970 RECENT MAJOR CHANGES DOSAGE AND ADMINISTRATION 21 May2012 INDICATIONS AND USAGE Bacillu See full prescribing information for Ferric Citrate Ferric Citrate ablet containing 210 mg of ferric iron equivalent to 1 g ferric citrate for ral se Initial U Approval 2014 INDICATIONS AND USAGE Ferric Citrate s a phosphate binder indicated for --------------------------RECENT MAJOR CHANGES---------------------------- Boxed Warning 04/15 Indications and Usage (1.1) 04/15 Dosage and Administration (2.1, 2.2) 04/15 Warnings a NDA 22-288/S-003 Reference ID: 3151309 NDA 22-288/S-003 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a histamine H receptor antagoni Dr Duncan Petty. Lecturer Practitioner. School of Health Care, University of Leeds. RCN Advanced Nurse Practitioner. Forum conference 2011. 10 top tips for safer prescribing and review of medicines. Dr Duncan Petty. Adults and Children 30 kg (66 lbs) or more: 0.3 to 0.5 mg (0.3 to 0.5 mL) intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary (2.1) Children 30 What’s different about paediatric prescribing. Children are just . small adults. NOT!. Vary in their developmental stages. Pre-term, neonates, infants, children, adolescents. Dynamic anatomy and physiology. 5.1Hypersensitivity5.2Exogenous Ochronosis5.3Effects on Endocrine System5.4Cutaneous ReactionsADVERSE REACTIONSUSE IN SPECIFIC POPULATIONS8.1Pregnancy8.3NursingMothers8.4Pediatric Use8.5Geriatric Use1 WARNING: LOSS OF BONE MINERAL DENSITY Women who use Depo-Provera Contraceptive Injection may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be Reference ID 4330857FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudom Dermatologic ToxicityTemporarily interruptPOTELIGEO for moderate or severe skin rashes Permanently discontinue POTELIGEO for lifethreatening rash 51InfusionReactionsTemporarily interruptfor any infusi BALVERSA2FULL PRESCRIBING INFORMATION INDICATIONS AND USAGEBALVERSA is indicated for the treatment of adult patients with locally advanced or chemotherapy including within 12 months of neoadjuvant treatment and adjust dosing as needed 22 51 constipation nausea and vomiting as needed 22 52 Peripheral Neuropathy Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed 2 Levoleucovorin for injection is not indicated for the treatment of pernicious anemia or megaloblastic anemia secondary to lack of vitamin B because of the risk of progression of neurologic manifestati